21 minutes | May 14, 2021

Biotech’s 30% Dip: Your Entry Point Into a Future Top Trend

Biotech stocks were once the darling of the stock market.

The SPDR Biotech Fund Index (NYSE: XBI) tracks companies focused on developing therapeutics and using genetics. The fund rose 70% from May 2020 to February 2021.

But, since February, investor sentiment in the biotech industry has cooled and prices have fallen nearly 30%.

Does this present a buy opportunity?

In today’s episode of The Bull & The Bear, Adam O’Dell, Charles Sizemore and I look at the biotech industry and give you our take on where it’s heading.

Be sure to also subscribe to our YouTube channel for more videos like my weekly Marijuana Market Update.

Have something you want us to talk about? Email thebullandthebear@moneyandmarkets.com and give us your thoughts.

Check out moneyandmarkets.com, and sign up for our free newsletters that deliver you the most important and unbiased financial news, commentary, and actionable advice.

Also, follow us on:

Facebook

Twitter

LinkedIn

Play
Like
Play Next
Mark
Played
Share